News
05-31-2018, 05:02 AM
Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, and Angsana Molecular & Diagnostics Laboratory Pte Ltd, a subsidiary of Parkway Pantai, announce a partnership to market the MammaPrint Breast Cancer Risk of Recurrence test and the BluePrint Molecular Subtyping test to physicians across Southeast Asia, including Singapore, Malaysia, Vietnam, Brunei and Myanmar.
More... (https://www.news-medical.net/news/20180531/Agendia-and-Angsana-partner-to-market-MammaPrint-BluePrint-breast-cancer-tests-in-Southeast-Asia.aspx)
More... (https://www.news-medical.net/news/20180531/Agendia-and-Angsana-partner-to-market-MammaPrint-BluePrint-breast-cancer-tests-in-Southeast-Asia.aspx)